Rocket Pharmaceuticals, Inc. Warrant

Law firm investigating Rocket Pharmaceuticals for potential securities fraud related to undisclosed clinical trial protocol changes and serious adverse events in RP-A501 study, which led to a 37% stock price drop.

Law firm alerts investors about potential securities fraud class action lawsuits for four companies, alleging misleading statements and undisclosed risks during specific class periods in 2024-2025.

Rosen Law Firm alerts Rocket Pharmaceuticals investors about a securities class action lawsuit alleging false statements regarding the effectiveness and safety of drug candidate RP-A501, with an important deadline on August 11, 2025.

Law Offices of Frank R. Cruz alerts investors about an upcoming August 11, 2025 deadline to participate in a securities fraud class action lawsuit against Rocket Pharmaceuticals following an FDA clinical hold on a Danon disease treatment trial after a patient's death.

Rocket Pharmaceuticals faces a class action lawsuit alleging misleading statements about its Phase 2 clinical trial for RP-A501, with claims of concealing serious adverse events including patient death, which led to an FDA clinical hold and stock price decline.